Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2930543 | 0.92 | MAPT (0.58) | MAPTPOLBLMNAGAAALDH1A1 | |
| SCHEMBL30781039 | 0.92 | MAPT (0.58) | MAPTPOLBLMNAGAAALDH1A1 | |
| SCHEMBL2934670 | 0.89 | MAPT (0.51) | MAPTPOLBLMNAGAAALDH1A1 | |
| SCHEMBL23247037 | 0.84 | MAPT (0.50) | MAPTPOLBLMNAGAAALDH1A1 | |
| SCHEMBL28186774 | 0.81 | MAPT (0.53) | MAPTPOLBLMNAALDH1A1MEN1 | |
| SCHEMBL3099808 | 0.78 | EPHX1 (0.59) | MAPTPOLBLMNAGAAALDH1A1 | |
| SCHEMBL4061833 | 0.78 | SMN1; SMN2 (0.60) | MAPTPOLBLMNAGAAALDH1A1 | |
| SCHEMBL6819449 | 0.77 | POLB (0.49) | MAPTPOLBLMNAGAAALDH1A1 | |
| SCHEMBL29974854 | 0.77 | MAPT (0.47) | MAPTPOLBLMNAGAAALDH1A1 | |
| SCHEMBL23579537 | 0.77 | MAPT (0.47) | MAPTPOLBLMNAGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2905272-B1 | Process for hydrogenating aromatic di- and polyamines to cycloaliphatic di- and polyamines | COVESTRO DEUTSCHLAND AG (DE) | 2016-11-23 | — | — | EP | claimed |
| US-9278906-B2 | Process for hydrogenating aromatic di- and polyamines to cycloaliphatic di- and polyamines | BAYER MATERIALSCIENCE AG (DE) | 2016-03-08 | — | — | US | claimed |
| EP-2905272-A1 | Process for hydrogenating aromatic di- and polyamines to cycloaliphatic di- and polyamines | Bayer MaterialScience AG (DE) | 2015-08-12 | — | — | EP | claimed |
| US-20150218083-A1 | PROCESS FOR HYDROGENATING AROMATIC DI- AND POLYAMINES TO CYCLOALIPHATIC DI- AND POLYAMINES | COVESTRO DEUTSCHLAND AG (DE) | 2015-08-06 | — | — | US | claimed |
| US-20230117592-A1 | LIPOXYGENASE INHIBITORS | SRI INTERNATIONAL (US) | 2023-04-20 | — | — | US | disclosed |
| EP-4081199-A2 | LIPOXYGENASE INHIBITORS | SRI International (US) | 2022-11-02 | — | — | EP | disclosed |
| CN-115135316-A | Lipoxygenase inhibitors | 思研（SRI）国际顾问与咨询公司 | 2022-09-30 | — | — | CN | disclosed |
| WO-2021133689-A2 | LIPOXYGENASE INHIBITORS | SRI INTERNATIONAL (US) | 2021-07-01 | — | — | WO | disclosed |
| EP-2905272-B1 | Process for hydrogenating aromatic di- and polyamines to cycloaliphatic di- and polyamines | COVESTRO DEUTSCHLAND AG (DE) | 2016-11-23 | — | — | EP | disclosed |
| US-9278906-B2 | Process for hydrogenating aromatic di- and polyamines to cycloaliphatic di- and polyamines | BAYER MATERIALSCIENCE AG (DE) | 2016-03-08 | — | — | US | disclosed |
| EP-2905272-A1 | Process for hydrogenating aromatic di- and polyamines to cycloaliphatic di- and polyamines | Bayer MaterialScience AG (DE) | 2015-08-12 | — | — | EP | disclosed |
| US-20150218083-A1 | PROCESS FOR HYDROGENATING AROMATIC DI- AND POLYAMINES TO CYCLOALIPHATIC DI- AND POLYAMINES | COVESTRO DEUTSCHLAND AG (DE) | 2015-08-06 | — | — | US | disclosed |
| US-20040198731-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-07 | — | — | US | disclosed |
| US-20040198732-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-07 | — | — | US | disclosed |
| US-20040198733-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-07 | — | — | US | disclosed |
| US-20040192693-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-09-30 | — | — | US | disclosed |
| EP-1418906-A1 | AMINOALKYL-SUBSTITUTED AROMATIC BICYCLIC COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | Aventis Pharma Deutschland GmbH (DE) | 2004-05-19 | — | — | EP | disclosed |
| US-20030212070-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-11-13 | — | — | US | disclosed |
| WO-2003015769-A1 | AMINOALKYL-SUBSTITUTED AROMATIC BICYCLIC COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218083-A1 | PROCESS FOR HYDROGENATING AROMATIC DI- AND POLYAMINES TO CYCLOALIPHATIC DI- AND POLYAMINES | DDT, HRH3, HRH4 | MAPT 2582/4885POLB 584/4885LMNA 4846/4885 |
| US-20030212070-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | PER2, CNR2, DDC | MAPT 3514/4885POLB 1943/4885LMNA 1397/4885 |
| US-20230117592-A1 | LIPOXYGENASE INHIBITORS | ALOX15B, ALOX12, ALOX5 | MAPT 2110/4885POLB 1414/4885LMNA 1170/4885 |
| US-20040192693-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | PER2, CNR2, DDC | MAPT 3514/4885POLB 1943/4885LMNA 1397/4885 |
| US-20040198731-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | PER2, CNR2, DDC | MAPT 3514/4885POLB 1943/4885LMNA 1397/4885 |
| US-20040198733-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | PER2, CNR2, DDC | MAPT 3514/4885POLB 1943/4885LMNA 1397/4885 |
| US-20040198732-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | PER2, CNR2, DDC | MAPT 3514/4885POLB 1943/4885LMNA 1397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.